UAE Liver Cancer Therapeutics Market Analysis

UAE Liver Cancer Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the UAE liver cancer therapeutics market will reach a value of $57.3 Mn from $14.7 Mn in 2022, growing at a CAGR of 18.6% during 2022-30. The liver cancer therapeutics in UAE is dominated by a few domestic pharmaceutical companies such as Neopharma, Julphar, and Medpharma. The liver cancer therapeutics market in UAE is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10AEPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the UAE liver cancer therapeutics will reach a value of $57.3 Mn from $14.7 Mn in 2022, growing at a CAGR of 18.6% during 2022-2030.

United Arab Emirates (UAE) is a high-income, developing country located in the Middle East bordering the Gulf of Oman and the Persian Gulf. According to the most recent WHO data published in 2020, the number of deaths from liver cancer in the Arab Emirates reached 96, accounting for 0.49 % of all deaths. The age-adjusted death rate in the Arab Emirates is 5.05 per 100,000 inhabitants, ranking it 98th in the world.

The Middle East and North Africa (MENA) region has a rising burden of HCC due to a high prevalence of viral hepatitis, particularly HCV infection, and a lack of adequate preventative and therapeutic measures. With an increasing frequency of fatty liver diagnoses, this could become the UAE's leading cause of liver transplants. UAE's government spent 5.5 % of its GDP on healthcare in 2020.

uae liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

The market's expansion can be due to factors such as the country's increasing prevalence of liver cancer, increased awareness of the condition, and increased spending on research & development of novel medicines for the treatment of liver cancer. The research further states that the increasing use of targeted treatments and immunotherapies in the treatment of liver cancer is projected to fuel market growth in the coming years. The UAE is an outstanding regional trading hub for businesses.

Market Restraints

Cultural and religious beliefs can influence some patients' willingness to seek out and receive liver cancer treatments. This can limit the size of the patient population and make it difficult for pharmaceutical companies to gain a footing in the market. Traditional remedies have a strong heritage in the UAE and can compete with Western-style therapies, including liver cancer therapeutics.

Competitive Landscape

Key Players

  • Neopharma: Neopharma is a UAE-based pharmaceutical company that develops and manufactures drugs for various diseases, including cancer. They have several cancer drugs in their portfolio, such as Abraxane and Eribilin
  • Julphar: Julphar is a UAE-based pharmaceutical company that develops and manufactures drugs for various diseases, including cancer. They have several cancer drugs in their portfolio, such as Capecitabine and Nolatrexed (a drug being studied for its potential in treating solid tumours)
  • Medpharma: Medpharma is a UAE-based pharmaceutical company that develops and manufactures drugs for various diseases, including cancer
  • Emirates Biotech Pharmaceutical Factory: Emirates Biotech Pharmaceutical Factory is a UAE-based pharmaceutical company that develops and manufactures drugs for various diseases, including cancer

Healthcare Policies and Reimbursement Scenarios

In the UAE, the regulatory body responsible for the approval of liver cancer therapeutics is the Ministry of Health and Prevention (MOHAP). The reimbursement of liver cancer therapeutics in the UAE is largely determined by the recommendations of health insurance companies, which evaluate the cost-effectiveness of medications and make recommendations about coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UAE Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Other Types

By Treatment (Revenue, USD Billion):

  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Ablation Therapy
  • Embolization Therapy

By Equipment (Revenue, USD Billion):

  • Computed Radiography
  • MRI
  • Sonography
  • Others

By Route of Administration (Revenue, USD Billion):

  • Oral
  • Intravenous

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 04 April 2023
Updated by: Anish Swaminathan

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up